» Articles » PMID: 32854646

Characterization of Longitudinal Transformation of T2-hyperintensity in Oligodendroglioma

Abstract

Background: Oligodendroglioma (ODG) are CNS resistant tumors characterized by their unique molecular signature, namely a combined deletion of 1p and 19q simultaneously to an IDH1/2 mutation. These tumors have a more favorable clinical outcome compared to other gliomas and a long-time survival that ranges between 10 and 20 years. However, during the course of the disease, multiple recurrences occur and the optimal treatment at each stage of the disease remains unclear. Here we report a retrospective longitudinal observation study of 836 MRI examinations in 44 ODG patients.

Methods: We quantified the volume of T2-hyperintensity to compute growth behavior in dependence of different treatment modalities, using various computational models.

Results: The identified growth pattern revealed dynamic changes, which were found to be patient-specific an did not correlate with clinical parameter or therapeutic interventions. Further, we showed that, surgical resection is beneficial for overall survival regardless the WHO grad or timepoint of surgery. To improve overall survival, an extent of resection above 50% is required. Multiple resections do not generally improve overall survival, except a greater extent of resection than in previous surgeries was achieved.

Conclusions: Our data aids to improve the interpretation of MRI images in clinical practice.

Citing Articles

Hydrocephalus Shunting in Supratentorial Glioblastoma: Functional Outcomes and Management.

El Rahal A, Cipriani D, Fung C, Hohenhaus M, Sveikata L, Straehle J Front Oncol. 2022; 12:796105.

PMID: 35223477 PMC: 8865077. DOI: 10.3389/fonc.2022.796105.

References
1.
Diamandis E, Gabriel C, Wurtemberger U, Guggenberger K, Urbach H, Staszewski O . MR-spectroscopic imaging of glial tumors in the spotlight of the 2016 WHO classification. J Neurooncol. 2018; 139(2):431-440. DOI: 10.1007/s11060-018-2881-x. View

2.
Delev D, Heiland D, Franco P, Reinacher P, Mader I, Staszewski O . Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system. J Neurooncol. 2018; 141(1):223-233. DOI: 10.1007/s11060-018-03030-w. View

3.
Jakola A, Skjulsvik A, Myrmel K, Sjavik K, Unsgard G, Torp S . Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol. 2017; 28(8):1942-1948. PMC: 5834105. DOI: 10.1093/annonc/mdx230. View

4.
Aghi M, Nahed B, Sloan A, Ryken T, Kalkanis S, Olson J . The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015; 125(3):503-30. DOI: 10.1007/s11060-015-1867-1. View

5.
Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F . NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009; 27(35):5874-80. DOI: 10.1200/JCO.2009.23.6497. View